04 November 2013 IHS Markit Life Sciences Expert
While the aging of the "baby boomer" population in the U.S. and the associated implications for increased healthcare costs have received ...
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Life Sciences Research and Analysis
Find timely insights, commentary and special reports from industry leading experts and analysts.
Industry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence.
Featured
Browse Content
-
-
04 November 2013 Maria McGee
In March of this year, we published an in-depth analysis on AMR in a special report titled, "Are we losing the fight against antimicrobial ......
-
31 October 2013 Gustav Ando
The IHS Healthcare & Pharma team is pleased to announce that we will again have a strong presence at the ISPOR 16th European Congress in Dublin...
-
29 October 2013 Milena Izmirlieva
Today, I had the privilege of making a presentation about health technology assessment (HTA) to an audience of pharmaceutical industry professionals...
-
24 October 2013 Kavita Rainova
As an analyst covering Ukraine on a daily basis I find most developments in the country focused on low-tech technologies in healthcare - such...
-
22 October 2013 Brendan Melck
On 1 October, the G-BA announced the completion of the first retroactive benefit assessment of a class of medicines under AMNOG. The class involved...
-
18 October 2013 Gustav Ando
The late CEO of Apple, Steve Jobs, famously quipped that "you can't connect the dots looking forward - you can only connect them looking ...
-
09 October 2013 Mark Hollis
I attended the African Pharmaceutical Summit, held recently in Tunisia, and noted that delegates appeared to rally behind the notion of pharmaceutical...
-
07 October 2013 Cameron Lockwood
GlaxoSmithKline and Theravance's Relvar Ellipta has found itself making multiple headlines lately- first as the result of a positive CHMP ......
-
02 October 2013 Margaret Labban
On 1 October, health insurance marketplaces were officially launched in the US, offering affordable health care coverage to millions of uninsured...
-
30 September 2013 Praful Mehta
Earlier this month, the European Society of Cardiology (ESC) concluded its most prestigious event - ESC Congress 2013 - amid much fanfare. The...
-
23 September 2013 Gustav Ando
In July, IHS launched its pharmaceutical Market Access Risk Scores (MARS), which are designed to quantify the relative risks of global pharmaceutical...
-
19 September 2013 Margaret Labban
On 10 September 2013, US-headquartered biopharmaceutical firm Hospira and South-Korean partner Celltrion became the first companies to gain marketing...
-
18 September 2013 Jing Zhang
My last trip back to China gave me a startling realization that the economy has improved beyond recognition. According to our estimate, China's...
-
12 September 2013 Gustav Ando
IHS Healthcare is attending ISPOR 4th Latin America Conference, 12-14 September, at the Hilton Buenos Aires. If you are attending the show, come...
-
09 September 2013 Praful Mehta
The weight loss industry is growing at an unprecedented rate - with diet drugs, weight loss programs, and unproven methods of lowering weight...
-
05 September 2013 Cameron Lockwood
With August 30th come and gone, the full impact of the Canadian province of Alberta's May 1st reduction in its generic price cap from 35% to...
-
03 September 2013 Cameron Lockwood
As outlined in my colleague Milena's post back in May, the biosimilars debate is quickly heating up on the US political scene. Just recently...
-
28 August 2013 Chiara Cochetti
The launch of ALBAmed, recently announced by the members of the Bolivarian Alliance for the Americas (ALBA), has made me further appreciate the...
-
23 August 2013 Marinoni, Gaelle
In the autumn of last year, France seemed on the brink of overhauling its pricing and reimbursement (P&R) framework by ditching its SMR/ASMR...
-
20 August 2013 Sophia Walker
After recently arriving back from my yearly holiday on a tick-infested island off of Cape Cod, Massachusetts, I have kept my eyes peeled for...
-
15 August 2013 Gaelle Marinoni
With France introducing mandatory economic evaluation for new innovative medicines from October 2013, relative effectiveness assessment (REA)...
-
05 August 2013 Maria McGee
With no specific treatments or vaccines currently available, along with the lack of knowledge about its mechanism, the threat of a global Middle...
-
23 July 2013 Floriane Reinaud
On 1 July, Croatia joined the European Union. This move could potentially have an effect not only on the Croatian pharmaceutical market, but...
-
18 July 2013 Marinoni, Gaelle
At the same time as the EMA's CHMP recommended the first two monoclonal antibody biosimilars for marketing approval in the European Union, the...
-
18 July 2013 Mark Hollis
Having previously, (in)famously, adopted stringent policies against the global brand drugs industry, Indian government pharmaceutical policy...
-
15 July 2013 Kavita Rainova
In the last few days, news has been circulating the media that Russian biosimilars manufacturer, Biocad, is looking for a foreign buyer. As was...
-
10 July 2013 Praful Mehta
At the height of the 'good old days' for the drug industry, and long before the emergence of financial crisis, pharmaceutical companies started......
-
08 July 2013 IHS Markit Life Sciences Expert
Since 2009, the French healthcare system has been in a state of relative turmoil, with high-profile media discussions over healthcare spend and...
-
02 July 2013 Brendan Melck
An amendment to Germany's law on medicines which is set for its final reading in the coming days is set to introduce changes which promise greater...
-
27 June 2013 Tania Rodrigues
Whilst in the midst of researching for a report on HTA in Latin America (and determined to improve my understanding of Spanish), I found myself...
-
24 June 2013 Margaret Labban
The US Supreme court unanimously ruled on Thursday (13 June) that naturally occurring human genes such as BRCA1 and BRCA2 cannot be patented...
-
19 June 2013 Mark Hollis
Burj Khalifa, oil, Palm Jumerira, austerity....ehhh? Austerity is not a word one would normally associate with the United Arab Emirates but two...
-
17 June 2013 Cameron Lockwood
Having explored the emerging interface between European regulators and payers as part of our recent study on what the pharmacovigilance reforms...
-
04 June 2013 Sophia Walker
Do I carry the BRCA mutation? I know I was not alone in asking myself this question after Angelina Jolie's revelation in an OpEd piece in the...
-
31 May 2013 Milena Izmirlieva
Last week I attended ISPOR's 18th annual international meeting in New Orleans, Louisiana. The theme of the event was "Finding the Patient in...
-
22 May 2013 Tericke Blanchard
The Medicare Part D drug benefit was introduced in January 2006 to improve care for the elderly population. Prior to implementation, 30% of Medicare...
-
20 May 2013 Federica Benassi
Two months after the election of the new Parliament, the new Italian Minister of Health Beatrice Lorenzin has outlined the main priorities for...
-
17 May 2013 Gustav Ando
In addition to our booth and presentations at ISPOR next week, The IHS Healthcare & Pharma team will have a strong presence at PBIRG, 19-22 May...
-
15 May 2013 Milena Izmirlieva
The dust has hardly settled following debates over the creation of health insurance exchanges - under the provisions of the Affordable Care Act...
-
14 May 2013 Gustav Ando
The IHS Healthcare & Pharma team is pleased to announce that we will again have a strong presence at the Annual International Meeting of ISPOR...
-
13 May 2013 Floriane Reinaud
With cost-containment policies implemented in a large number of countries, the economic downturn has also had a large impact on the healthcare...
-
08 May 2013 Brendan Melck
The temperature is rising again in the German pharmaceutical sector, with the recent publication by the G-BA of the schedule for the first six...
-
07 May 2013 Cameron Lockwood
With the end of April come and gone, the EMA has, as promised, published the final advice from each of the five clinical trial advisory groups...
-
02 May 2013 Tericke Blanchard
The US Congress is again discussing development of a nationwide tracking system for pharmaceutical products that would replace state programs....
-
30 April 2013 Milena Izmirlieva
As Sir Andrew Dillon, Chief Executive Officer of the United Kingdom's National Institute for Health and Clinical Excellence (NICE) recently announced...
-
24 April 2013 Maria Bertram
I recently attended the BioMedical Device conference held in Boston, Massachusetts. The event brought together several hundred attendees focused...
-
22 April 2013 Chiara Cochetti
Recently I attended an interesting web conference on the topic of "Achieving effective market access in Latin America". The talk gathered ......
-
17 April 2013 Mark Hollis
April 5, 2013, marked the 1000 day until the end of the Millennium Development Goals (MDG) - a 15 year program to bring about meaningful changes...
-
15 April 2013 Gustav Ando
Depending on how you define the proverbial "patent cliff", we are now roughly well into our third year of this unusually dense constellation...
-
10 April 2013 Gustav Ando
Last week, IHS commented on a new study published in the New England Journal of Medicine which found that U.S. spending on dementia-related illnesses...
-
09 April 2013 Cameron Lockwood
Since publication in February 2011 of its Geriatric Medicines Strategy, the EMA has been undertaking various initiatives to ensure that the development...
-
05 April 2013 Sophia Walker
I've never been a fan of the term 'War on Cancer', but recent events have made me see the lure of this moniker. If a war is what is ...
-
28 March 2013 IHS Markit Life Sciences Expert
With the long-awaited formal transition of power in China completed at the National People's Congress (NPC) on 18 March, there is a sense that...
-
19 March 2013 Kavita Rainova
At a recent conference I attended, dedicated to the regulatory affairs in Russia, CIS, and Turkey, the overriding message from pharma company...
-
14 March 2013 Cameron Lockwood
As of April 1st 2013, the prices of six commonly-prescribed generic medicines will fall across Canada, down to 18% of the price of the branded...
-
12 March 2013 Praful Mehta
Tresiba, a basal insulin, was recently launched by NovoNordisk in Japan(the drug was approved in Europe in October 2012). The company has hailed...
-
11 March 2013 IHS Markit Life Sciences Expert
It was a cold and dreary day, with a major snowstorm responsible for the closing of offices throughout the Washington, DC area. The weather outside...
-
06 March 2013 Tania Rodrigues
After a swift passage through the security check-point, that included an airport style search, I was officially inside the UK House of Commons...
-
01 March 2013 Cameron Lockwood
Since I last wrote about the 340B debate in the US, the controversy over this outpatient drug discount programme - originally designed to address...
-
27 February 2013 Marinoni, Gaelle
The new European pharmacovigilance legislation was passed at the end of 2010 with large portions of it implemented last summer. With its emphasis...
-
19 February 2013 Jing Zhang
China's economy has escaped a hard landing. Real GDP growth strengthened to 7.9% year-on-year in the fourth quarter, up from 7.4% in the third...
-
11 February 2013 IHS Markit Life Sciences Expert
OMS-Europe statistics show that France lags behind its European counterparts in terms of vaccination rates. The French government is also of...
-
06 February 2013 Cameron Lockwood
A joint post by Cameron Lockwood and Gaëlle Marinoni In its February 2013 edition, French monthly publication Prescrire released a list of marketed...
-
29 January 2013 Praful Mehta
On 25th December 2012, Journal of American College of Cardiology (JACC) published its most comprehensive report on the worldwide environment...
-
21 January 2013 Floriane Reinaud
Limits on pharmaceutical reimbursement--but improvements on their way The Russian pharmaceutical market has steadily increased over time, commonly...
-
18 January 2013 Kavita Rainova
In a dramatic move, United Kingdom's National Institute for Health and Clinical Excellence (NICE) this week has recommended the use of tamoxifen...
-
16 January 2013 Anne-Charlotte Ackermann
International reference pricing (IRP) was at the centre of discussions and dominated the debates in a number of prominent conferences this past...
-
08 January 2013 Cameron Lockwood
With the start of the New Year, I thought I would provide an update on the clinical trial data transparency debate. For while 2013 has just begun...
-
03 January 2013 Tania Rodrigues
As 2012 drew to a close, the Portuguese Ministry of Health took stock of the most notable developments that rocked the country's healthcare arena...
-
01 January 2013 Farah Ramadan
The 2012 Access to Medicine Index (AMI) results have recently been published with GlaxoSmithKline (GSK) securing the leader spot yet again followed...
-
27 December 2012 Floriane Reinaud
Sustainability of the national healthcare insurance rapidly challenged Healthcare coverage started to be implemented in South Korea in 1977 and...
-
20 December 2012 Gustav Ando
As 2012 draws to a close, the IHS Healthcare and Pharma team has taken the opportunity to look at the upcoming developments in R&D, P&R, M&A...
-
18 December 2012 Chiara Cochetti
The new sustainability plan presented at the end of October by Madrid's healthcare minister Jose Fernandez Lasquetty envisaging partial privatisation...
-
13 December 2012 Gustav Ando
IHS Healthcare had seven abstracts accepted for poster presentation at the 15th European Congress of ISPOR in Berlin (3-7 November). If you were...
-
07 December 2012 Gaelle Marinoni
Last week, after 4 months of data crunching and analysis, we published our latest study entitled Dynamic pharmaceutical pricing 2012: What is...
-
03 December 2012 Floriane Reinaud
European Turmoil 2012: Follow-up on the webcast held this month on drug prices and market access across Europe Two weeks ago IHS Global Insight...
-
29 November 2012 Brendan Melck
The Greek authorities recently implemented prescription by international non-proprietary name (INN), to much criticism and concern. We looked...
-
27 November 2012 Chiara Cochetti
While attending the Conference "Pharmaceutical Regulatory Affairs in Latin America" that took place at the London Cavendish Hotel from the 29th......
-
26 November 2012 Mark Hollis
Indian clinical trials are back in the spotlight with the recent BBC Newsnight piece examining a brewing controversy over drug testing in the...
-
20 November 2012 Cameron Lockwood
I've written before about "joint working" here in the UK – a practice which sees industry and the NHS pool resources to improve patient outcomes....
-
14 November 2012 Tericke Blanchard
The Food and Drug Administration (FDA) regulates a continually growing number of products that originate from over 150 countries. Furthermore...
-
14 November 2012 Floriane Reinaud
Tomorrow, the IHS Healthcare and Pharma team will host a webinar on the European turmoil and the impact the economic downturn has had on the...
-
12 November 2012 Farah Ramadan
Germany's e-health card (eGK) initiative is finally seeing light, six years since its inauguration in 2006. After its suspension in 2010, the...
-
08 November 2012 Sophia Walker
Boehringer Ingelheim must be taking a huge sigh of relief this week. The US FDA has released the results of a Mini-Sentinel assessment that found...
-
05 November 2012 Floriane Reinaud
With pharmaceutical spending largely increasing in CEE countries, cost-containment policies are now in the radar of those governments. To get...
-
30 October 2012 Gustav Ando
The IHS Global Insight Healthcare and Pharma service is pleased to announce that we will again have a strong presence at the Annual European...
-
28 October 2012 Milena Izmirlieva
On 6 November, Americans will be voting for President, for all seats in the House of Representatives, and a third of seats in the Senate. But...
-
25 October 2012 Cameron Lockwood
Against the general backdrop of debate in the countdown to the US presidential election, another, slightly more obscure debate has been intensifying...
-
19 October 2012 Chiara Cochetti
The wave of austerity measures enforced by the Spanish government since August 2011 has undoubtedly produced controversial results so far. While...
-
17 October 2012 Anne-Charlotte Ackermann
The domain of drug cost-effectiveness evaluation is definitively in turmoil in Europe; after Germany and its incremental benefit scores, France...
-
12 October 2012 Cameron Lockwood
As Canada's provinces and territories begin tackling the 2014 health accord negotiations, they have also been busy ramping up efforts for the...
-
10 October 2012 Gustav Ando
For all intents and purposes it appeared, back in the summer, as if Lilly's once highly-touted solanezumab (sola) would join Pfizer's ...
-
09 October 2012 Brendan Melck
Cost-containment policies focusing on bringing down the prices of reimbursed medicines in three neighbouring countries in the Central and Eastern...
-
05 October 2012 Maria McGee
The pharmaceutical industry has to compete with Public Health (PH) interventions when demonstrating an economic case for their products and/...
-
03 October 2012 Sophia Walker
As someone who is intrigued by the interplay of cancer and diabetes, the findings that diabetes drug metformin may have benefit as a cancer treatment...
-
01 October 2012 Floriane Reinaud
In one of my previous posts I looked into time to pricing and price levels for innovative drugs in the top 5 European markets. For this blog...
-
28 September 2012 Milena Izmirlieva
As the battle for hearts and minds in the run-up to US presidential elections heats up, a newly published report by the US Congressional Budget...
-
27 September 2012 Cameron Lockwood
Around this time last year, the Gillard government, in agreement with Medicines Australia, the Consumers Health Forum, and the Generic Medicines...
-
25 September 2012 Tania Rodrigues
I wished I had practiced French beyond my school days was among my first thoughts when I attended the XXII congress of the Latin Association...
-
21 September 2012 Cameron Lockwood
The dust rarely has time to settle in the NHS; currently in the midst of major reforms, England's health service has undergone a variety of ......
-
18 September 2012 Chiara Cochetti
A recent opportunity to present a paper on the Cuban healthcare system has given me food for thought about the use of an advanced biotech sector...
-
14 September 2012 Zhang, Jing
While attending the ISPOR 5th Asia-Pacific Conference at the Taipei International Convention Center in early September, I was impressed by Taiwan's...
-
10 September 2012 Farah Ramadan
Reimbursement of medical devices remains a particularly challenging area. In our recent study on Optimizing Medical Devices Launches in major...
-
05 September 2012 Praful Mehta
On 11th Aug 2012, Lancet published the article titled "Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an...
-
28 August 2012 Floriane Reinaud
The current economic turmoil has impacted the world. However, some countries have been hit harder than others, notably Spain and Greece. The...
-
27 August 2012 IHS Markit Life Sciences Expert
While attending ISPOR's 17th Annual International Meeting, held recently in Washington, D.C., I noticed two common themes across the myriad sessions...
-
21 August 2012 Praful Mehta
On 25 August 2012, in Munich, Germany, 35,000 Cardiologists from all over the world will get together to participate in one of the most prestigious...
-
20 August 2012 Anne-Charlotte Ackermann
The implementation of Germany's AMNOG pricing reform is facing its first significant hurdle due to the inadequacy of pharmacy software to implement...
-
Pharma Budget Impact Models (BIMs) in practice: Creating a better model for manufacturers and payers
14 August 2012 April Semilla
This year's ISPOR , in Washington DC, provided a great variety of issue panels for the attendees, with topics falling under the umbrella of three...
-
09 August 2012 IHS Markit Life Sciences Expert
As we wrote about in March, telehealth provides the ability to extend healthcare delivery to patients' homes by monitoring vital signs and managing...
-
07 August 2012 Tericke Blanchard
Rapid expansion of medical technologies and budget pressures are driving changes to evidence requirements for demonstration of cost-effectiveness....
-
01 August 2012 IHS Markit Life Sciences Expert
On the first day of last month's ISPOR in the United States, Michael Drummond of the University of York, Alistair McGuire of the London School...
-
30 July 2012 Marinoni, Gaelle
A few weeks ago, I attended the 9th annual HTAi meeting in Bilbao, Spain, where there were a few sessions on, and a lot of debate over, the ......
-
26 July 2012 Cameron Lockwood
In what may prove to be a reversal of fortune for gene therapy Glybera (alipogene tiparvovec), last week, the EMA's CHMP issued a positive ......
-
24 July 2012 Marinoni, Gaelle
Following up on our study on payer-industry partnerships in the developed markets, we recently completed a similar study in the BRIC-MT markets...
-
23 July 2012 IHS Markit Life Sciences Expert
Once again, comparative effectiveness research was a hot topic at ISPOR this past May. There continues to be a pressing need to gather findings...
-
19 July 2012 Milena Izmirlieva
Late last week, the United Kingdom's NICE issued its first ever so called Evidence Summary for a new drug. The first summary is for Japanese...
-
18 July 2012 Gustav Ando
This week, the US FDA approved the first ever treatment for so called "pre-exposure prophylaxis", or PrEP, in HIV/AIDS: Gilead's Truvada ...
-
17 July 2012 Milena Izmirlieva
It was just announced that GlaxoSmithKline will take over Human Genome Sciences, its longtime research partner, for $3.6 billion. Watch our Senior...
-
16 July 2012 Sophia Walker
As a type 1 diabetic, I relished the news that Johnson & Johnson's (J&J's) subsidiary Janssen has joined the crusade to treat diabetes ...
-
10 July 2012 Tania Rodrigues
The Ministry of Health (MoH) signed a new protocol with branded drug industry association Apifarma on 14 May, which is, in theory, more demanding...
-
06 July 2012 Cameron Lockwood
As IHS team members made their way from the 9th HTAi annual meeting in Bilbao to the TOPRA-organised conference on pharmacovigilance in Brussels...
-
05 July 2012 Tericke Blanchard
Earlier this month I attended the ISPOR Annual Meeting (June 4-6) in Washington, DC, where the theme was "Improving Health Care Efficiency."...
-
04 July 2012 Gustav Ando Jing Zhang
By Jing Zhang and Gustav Ando The US Centers for Medicare and Medicaid Services (CMS) recently projected healthcare spending in the US to grow...
-
03 July 2012 Floriane Reinaud
Social Protection Targeted by Sub-Saharan Governments Aside from North-African countries, where public healthcare insurance is often already...
-
28 June 2012 Gustav Ando
So in the end, it was the kind of outcome that had some people cheering, and left others bitterly angry. Few Supreme Court opinions have been...
-
26 June 2012 Cameron Lockwood
A number of IHS Healthcare team members are currently attending the 9th annual HTAi meeting in Bilbao. It seems somehow fitting that, in a city...
-
21 June 2012 Brendan Melck
Poland's Reimbursement Act has led to dramatic changes in the pricing and reimbursement (P&R) landscape in Poland, although virtually no ...
-
19 June 2012 Floriane Reinaud
As the debate over the impact of economic austerity on healthcare delivery continues to rage across Southern Europe, it perhaps comes as little...
-
14 June 2012 Gustav Ando
Like the proverbial bolt from clear blue sky, little-known US drug development firm Ophthotec Corp yesterday unveiled compelling evidence for...
-
11 June 2012 Brendan Melck
The Italian health minister Renato Balduzzi has indicated that if doctors do not abide by the spirit of recent laws on generic substitution...
-
05 June 2012 Cameron Lockwood
This April, Glybera (alipogene tiparvovec), a gene therapy developed by Dutch firm Amsterdam Molecular Therapeutics (AMT) for use in patients...
-
31 May 2012 Anne-Charlotte Ackermann
The election of François Hollande to the French presidency has brought a wind of change in Europe's handling of the Eurozone crisis. But while......
-
30 May 2012 Sophia Walker
The death of the Lockerbie bomber, Abdelbaset Ali Mohmed al-Megrahi, from metastatic prostate cancer, has thrust Johnson & Johnson's prostate...
-
25 May 2012 Milena Izmirlieva
In a highly controversial move, the United Kingdom's government vetoed the release of a risk register on healthcare reform earlier this month....
-
23 May 2012 Praful Mehta
In February, I wrote a blog post about the importance of Patient Adherence and its effects on market access. Since then I've had numerous discussions......
-
18 May 2012 Floriane Reinaud
As Greece continues to experience major economic - and now political - turmoil, the pharmaceutical industry has been hit hard by various ...
-
16 May 2012 Brendan Melck
Hungary's latest austerity plan, dubbed the Széll Kálmán Plan 2.0 - following on from last year's first Széll...
-
15 May 2012 Gaelle Marinoni
GlaxoSmithKline's (GSK) Benlysta (belimumab) is the first therapy to be approved for the treatment of lupus in over 50 years. Yet, despite ......
-
10 May 2012 Cameron Lockwood
The Association of the British Pharmaceutical Industry (ABPI) has been busy at work on the "joint working" front. At the end of March, the ......
-
07 May 2012 Gustav Ando
Tolero Pharma is the third drug firm in a matter of months to make a decisive investment in the Bruton's tyrosine kinase (Btk) research area...
-
03 May 2012 Gustav Ando
During the last week or so, with a flurry of quarterly results presentations from the drug industry, there has also been a major change in leadership...
-
29 April 2012 Farah Ramadan
Recently I was privileged to participate at the East Africa Healthcare Investment Summit 2012, held in Kampala, Uganda on 18th and 19th April...
-
25 April 2012 Cameron Lockwood
Independent researchers have sparked something of a brouhaha this month over access to clinical study reports - the industry's raw clinical ......
-
23 April 2012 Gaelle Marinoni
With the introduction of AMNOG early last year, Germany jumped on the relative effectiveness assessment (REA) bandwagon by linking pharmaceutical...
-
18 April 2012 Anu Bharath
With the second largest population in the world, a growing middle class, and the country set to be the epicentre for conditions such as diabetes...
-
18 April 2012 Farah Ramadan
I'm currently at the East Africa Healthcare Investment Summit 2012 in Kampala, Uganda and have just participated in a hugely interesting panel...
-
12 April 2012 Gustav Ando
Lost patents. Risky, expensive R&D. The end of the traditional blockbuster drug era. Let's face it: when it comes to sustainable, long-term ......
-
09 April 2012 Floriane Reinaud
With the French presidential election just around the corner, now's the time to take a look at the potential impacts the top candidates could...
-
03 April 2012 Praful Mehta
When I consider the current state of global healthcare systems and stakeholder engagement, I get a strong sense that there's huge confusion ......
-
02 April 2012 Gustav Ando
It is over ten years since a new erythropoiesis-stimulating agent (ESA) reached the market, despite the fact that there has been a significant...
-
29 March 2012 Tania Rodrigues
Whilst conducting research on the Brazilian market for our latest multi-client study: The New REAlity of Relative Effectiveness - International...
-
23 March 2012 Milena Izmirlieva
I've been pondering this question in light of three things which happened in quick succession in the past few days: First the country's ...
-
22 March 2012 Farah Ramadan
While the medical industry is increasingly buzzing with concepts such as telemedicne, telehealth, telecare, m-health, we are yet to see how long...
-
18 March 2012 Cameron Lockwood
Earlier this month, GlaxoSmithKline (GSK) and a number of collaborators announced an innovative new study pertaining to Relovair, the company's...
-
16 March 2012 Sophia Walker
That is the million dollar question floating around the healthcare world, and particularly the cancer world. For every study heralding the benefits...
-
09 March 2012 Milena Izmirlieva
When German pharma company Merck Serono announced job cuts two weeks ago warning bells sounded through the pharma world. Job cuts and restructuring...
-
04 March 2012 Cameron Lockwood
Towards the end of last month, the European Medicines Agency (EMA) released its first batch of good pharmacovigilance practices (GVP) modules...
-
28 February 2012 Gustav Ando
Monday (27th February) saw Big Pharma make another major investment into the collection of very rare disorders grouped under the umbrella term...
-
23 February 2012 Gustav Ando
This week saw relatively disappointing Phase II clinical results published for Gilead Science's polymerase inhibitor GS-7977 in Hepatitis C genotype...
-
23 February 2012 Praful Mehta
The pharmaceutical industry is on a major defensive as substantial losses in revenues coupled with declining R&D productivity have threatened...
-
16 February 2012 Anu Bharath
The economic turmoil of recent years has of course affected the pharma industry, albeit belatedly. While the downturn began in 2008, it took...
-
13 February 2012 Floriane Reinaud
In my work developing and analysing our database of global drug prices, I frequently come across interesting pricing trends - particularly in...
-
08 February 2012 Cameron Lockwood
Saying that social media is big news in healthcare and pharma is something of an understatement - it seems the entire industry is abuzz with...
-
06 February 2012 Cameron Lockwood
Thanks to everyone who joined us for today's webcast. As promised we've posted the slides from the session at the bottom of this post. As we...
-
05 February 2012 Anu Bharath
Many people familiar with the NICE health technology assessment (HTA) methodologies would agree that access to orphan drugs has been a contentious...
-
03 February 2012 Gustav Ando
Three years ago I wrote an analysis on what was then a relatively little-known Phase III candidate: masitinib, which is being developed for a...
-
02 February 2012 Anne-Charlotte Ackermann
2012 is already a busy period for German watchdog IQWiG. With five early benefit assessments published since the New Year, and three more to...
-
01 February 2012 Farah Ramadan
Last week I attended the Medical Device Directive and the Recast conference in Brussels. As the name suggests, the conference's main focus was...
-
30 January 2012 Brendan Melck
A number of European Union (EU) countries are drawing considerable attention to themselves at the moment - for all the wrong reasons. Recently...
-
26 January 2012 Praful Mehta
Yesterday I was privileged to speak at the Pharmaceutical Product Lifecycle Management Conference in London. After meeting with the industry's...
-
23 January 2012 Marinoni, Gaelle
At the end of December 2011, France finally passed into law its much discussed pharmacovigilance reform. In the aftermath of the German healthcare...
-
20 January 2012 Milena Izmirlieva
If Primary Care Trust (PCT) managers in the United Kingdom were a bit worried about government plans for the introduction of a NICE Compliance...
-
17 January 2012 Farah Ramadan
While we all recognise the biological differences between women and men, healthcare hasn't always been viewed through a gender lens. This is...
-
16 January 2012 Sophia Walker
I've been covering oncology market access trends for three years now, and I've been in the oncology world for longer still. At the close of ......
-
12 January 2012 Cameron Lockwood
2011 was a notable year for medical devices in the US (and indeed further afield - see our post on the implications of the PIP breast implant...
-
10 January 2012 Marinoni, Gaelle
One of the hot healthcare topics of the moment is the Poly Implant Prosthese (PIP) breast implant cancer scare, which has already led France...
-
06 January 2012 Floriane Reinaud
Being responsible for a database that provides drug prices in more than 36 countries, I regularly observe price trends and compare prices between...
-
20 December 2011 Gustav Ando
It seems the global pharma industry is under attack from all angles. On the one hand, the creative engine of the industry is drying up as R&D...
-
18 December 2011 Cameron Lockwood
Having recently participated in an IHS study on the European hospital market, lately I've been thinking about how the events unfolding in the...
-
14 December 2011 Anu Bharath
Last month I attended the ISPOR Congress in Madrid, and I have to say it didn't disappoint. On day three I watched a panel session addressing...
-
13 December 2011 Gaelle Marinoni
We recently published a study on the partnerships between the pharmaceutical industry and payers, which involved interviews with national, regional...
-
11 December 2011 Milena Izmirlieva
Last week the United Kingdom's government gave us the strongest indication so far of how significant the role of the country's health ...
-
05 December 2011 Brendan Melck
Delays in payments - whether directly to pharmaceutical companies, or to wholesalers and pharmacies - have become a widespread phenomenon across...
-
01 December 2011 Gustav Ando
Today, 1 December 2011, is World AIDS Day. For many, it is a time to reflect on the tragedy - personal or otherwise - that this most vicious...
-
29 November 2011 Praful Mehta
Today, 30 November 2011, will go down in the pages of history as one of the most symbolic and important days for the global pharmaceutical industry...
-
25 November 2011 Gustav Ando
NICE guidance in six months, you say? And a positive appraisal? Believe it or not, this is what has actually happened to Eliquis (apixaban)...
-
16 November 2011 Gustav Ando
Upon yesterday's FDA approval of Incyte Corp's Jakafi (ruxolitinib), the first-ever drug for a debilitating bone marrow condition called ...
-
14 November 2011 Gustav Ando
No sooner had our plane landed after last week's ISPOR European Congress in Madrid, than we had calls from several delegates requesting more...
-
11 November 2011 Sophia Walker
With the recent deaths of Steve Jobs and Ralph Steinman, pancreatic cancer is a hard topic to avoid. Nothing instils fear in me quite like pancreatic...
-
07 November 2011 Gustav Ando
It's November again, and I'm blogging live from the ISPOR 14th Annual European Congress in a very muggy Madrid. At this year's event, one ......
-
04 November 2011 Praful Mehta
Lately I've been wondering what is causing the decline in the number of pipeline assets focusing on cardiovascular diseases (CVDs). Is it the...
-
28 October 2011 Aparna Krishnan
As I write this post, the world's largest drug in revenue terms, Lipitor (atorvastatin), is about five weeks away from facing its first generic...
-
25 October 2011 Milena Izmirlieva
Biosimilars - and why they are not making faster inroads into European markets - was one of the key topics discussed at the Generics and ...
-
21 October 2011 Praful Mehta
Diabetes is slowly gaining epidemic proportions with an estimated 400 million people likely to suffer from the disease by 2030. Will any drug...
-
10 October 2011 Jing Zhang
I recently developed a healthcare forecast report for the World Markets Healthcare Service, which looked at factors contributing to global healthcare...
-
06 October 2011 Gustav Ando
We're blogging live from the IHS-sponsored Oncology Market Access 2011 Conference in the "Eternal City" of Rome, where the focus has been...
-
05 October 2011 Sophia Walker
Soon after finishing a report for the World Markets Healthcare Service on the relationship between migration and healthcare, I boarded a flight...
-
05 October 2011 Cameron Lockwood
Given the range and complexity of medical devices and diagnostics, it's no surprise that medical device regulation is fast evolving. While the...
-
29 September 2011 Brendan Melck
Poland's Reimbursement Act - or to give its full, official name, the Act on the Reimbursement of Medicines, Foodstuffs Intended for Particular...
-
27 September 2011 Milena Izmirlieva
I'm currently at the Generics and Biosimilars Strategies EMEA Conference in Istanbul and have just participated in a panel discussion which examined...
-
21 September 2011 Marinoni, Gaelle
It seems to me that over the course of the last decade, increased market access barriers in top-tier markets have led the industry to take an...
-
21 September 2011 Aparna Krishnan
The US Federal Drug Administration (FDA) recently issued a notification over new safety fears regarding off-label use of Genentech's Avastin...
-
21 September 2011 Praful Mehta
I recently attended the European Society of Cardiology Congress in Paris, an exciting and overwhelming event with 32,000 attendees from across...
-
21 September 2011 Marinoni, Gaelle
A few months back we held a webcast that looked at the potential impact of AMNOG on the pharmaceutical industry. In the webcast we predicted...
1 2